Atlas Trials

Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)

Clinical trial NCT03534492 · COMPLETED

Trial details

NCT number
NCT03534492
Sponsor
Spanish Oncology Genito-Urinary Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2018-11-16
Primary completion
2020-03-16
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.